Aberrant expression of LMO2 through chromosomal translocation or a somatically acquired neomorphic promoter occurs in 50% of T-cell acute lymphoblastic leukemia (T-ALL)17,18. This evidence concerns the gene LMO2 and acute lymphoblastic leukemia.